Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Stefan Langhammer"'
Autor:
Dennis Gürgen, Theresia Conrad, Michael Becker, Susanne Sebens, Christoph Röcken, Jens Hoffmann, Stefan Langhammer
Publikováno v:
Communications Biology, Vol 5, Iss 1, Pp 1-10 (2022)
The identification of novel therapeutic strategies for advanced non-small cell lung cancer (NSCLC) is essential as the outcome of most of these patients is poor. Here the authors provide a proof-of concept that specific low-dose drug combinations can
Externí odkaz:
https://doaj.org/article/92f28987a8ba465c999b6d45aa1fdeb2
Autor:
Dennis Gürgen, Theresia Conrad, Michael Becker, Susanne Sebens, Christoph Röcken, Jens Hoffmann, Stefan Langhammer
Publikováno v:
Cancer Research. 82:3095-3095
Background: Non-small cell lung cancer (NSCLC) is commonly diagnosed at advanced stages with limited treatment options particularly in tumors without targetable driver mutations. Methods: Considering previously published criteria for selecting drug c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2c62b93f1722b0d5cfa29b61f7cbbc5
https://doi.org/10.1158/1538-7445.am2022-3095
https://doi.org/10.1158/1538-7445.am2022-3095
Autor:
Christoph Roecken, Theresia Conrad, Dennis Guergen, Susanne Sebens, Michael Becker, Jens Hoffmann, Stefan Langhammer
Non-small cell lung cancer (NSCLC) is commonly diagnosed at advanced stages limiting treatment options. Although, targeted therapy has become integral part of NSCLC treatment therapies often fail to improve patient’s prognosis. Based on previously
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a417eeb363896ce2cfeac53685509cfb
https://doi.org/10.1101/2021.10.23.465545
https://doi.org/10.1101/2021.10.23.465545
Autor:
Joachim Scheerer, Stefan Langhammer
Publikováno v:
Oncotarget
// Stefan Langhammer 1 and Joachim Scheerer 1 1 Life Science Consulting, Hirschweg, Burgwedel, Germany Correspondence to: Stefan Langhammer, email: // Keywords : NSCLC, targeted therapy, EGFR, angiogenesis Received : December 16, 2016 Accepted : Marc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31a3f1c7bed47892718e1e0feda36a3e
https://doi.org/10.18632/oncotarget.16674
https://doi.org/10.18632/oncotarget.16674
Autor:
Dennis Gürgen, Theresia Conrad, Michael Becker, Susanne Sebens, Christoph Röcken, Jens Hoffmann, Stefan Langhammer
Publikováno v:
Communications Biology
Communications Biology, Vol 5, Iss 1, Pp 1-10 (2022)
Communications Biology, Vol 5, Iss 1, Pp 1-10 (2022)
Non-small cell lung cancer (NSCLC) is commonly diagnosed at advanced stages limiting treatment options. Although, targeted therapy has become integral part of NSCLC treatment therapies often fail to improve patient’s prognosis. Based on previously
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6654d917294441cf87e9e1cb331cb78a
https://pubmed.ncbi.nlm.nih.gov/35039644
https://pubmed.ncbi.nlm.nih.gov/35039644
Autor:
Stefan Langhammer
Publikováno v:
Oncology Reports
Despite more than 70 years of research concerning medication for cancer treatment, the disease still remains one of the leading causes of mortality worldwide. Many cancer types lead to death within a period of months to years. The original class of c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3863146fe3adb88b6d1595838f70ff11
https://doi.org/10.3892/or.2013.2631
https://doi.org/10.3892/or.2013.2631
Publikováno v:
Targeted Oncology. 6:155-162
Serum lactate dehydrogenase (LDH) is a well-known clinical surrogate parameter. A high activity of LDH is associated with a poor prognosis in different tumor types. Here we demonstrate by a gene silencing approach that LDH-A is critical for in vivo b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf01017323eadfd875f84adc618d45dc
https://doi.org/10.1007/s11523-011-0184-7
https://doi.org/10.1007/s11523-011-0184-7
Publikováno v:
Antiviral Research. 89:119-123
A major challenge in the development of vaccines against retroviruses is the induction of neutralizing antibodies since they prevent infection of the cells where the virus may persist. The transmembrane envelope (TM) protein contains highly conserved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36128631e331bd8fb3f61efddc8d5674
https://doi.org/10.1016/j.antiviral.2010.11.011
https://doi.org/10.1016/j.antiviral.2010.11.011
Publikováno v:
Vaccine. 23:3341-3348
Neutralising antibodies specific for feline leukaemia virus (FeLV) were induced by immunisation with recombinant FeLV transmembrane envelope protein p15E. Epitope mapping revealed two epitopes located in similar regions to those previously identified
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dc19abcdcd31d0fee3e1e6a021ca196
https://doi.org/10.1016/j.vaccine.2005.01.091
https://doi.org/10.1016/j.vaccine.2005.01.091
Autor:
Barclay, Nicola L.1, Burn, Edward1,2, Delmestri, Antonella1,2, Duarte-Salles, Talita3,4,5, Golozar, Asieh6,7, Man, Wai Yi1, Tan, Eng Hooi1, Tietzova, Ilona8,9, N'Dow, James10, Witjes, Wim10, Smith, Emma Jane10, Bezuidenhout, Carla10, Collen, Sarah10, Plass, Karin10, Blum, Torsten Gerriet10, Borkowetz, Angelika10, Willemse, Peter-Paul10, Cornford, Philip10, Dabestani, Saeed10, Schlief, Maurice10
Publikováno v:
Scientific Reports. 8/17/2024, Vol. 14 Issue 1, p1-16. 16p.